REVIEW article
Front. Med.
Sec. Translational Medicine
Multifaceted Mechanisms and Targeted Delivery of Mesenchymal Stem Cell-derived Exosomes in Cardiovascular Diseases: A Translational Medicine Perspective
Provisionally accepted
- Shanghai PuTuo District Center Hospital, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
As cardiovascular disease (CVD) is the leading cause of death worldwide, its prevention and treatment is urgent and new therapeutic targets are urgently needed. Mesenchymal stem cell-derived exosomes (MSC-Exo) have emerged as promising nanotherapeutics due to their regenerative capacity, low immunogenicity, and multilineage differentiation potential. This review systematically integrates the therapeutic mechanisms of MSC-Exo in seven major cardiovascular indications, including myocardial infarction, myocardial ischemia-reperfusion injury, atherosclerosis, heart failure, cardiomyopathy, myocarditis, and pulmonary hypertension, while exploring advanced engineering strategies to enhance its efficacy. Through comprehensive analysis of current preclinical studies, we demonstrated that MSC-Exo mainly exerts cardioprotective effects by promoting angiogenesis, inhibiting apoptosis, fibrosis, inhibiting inflammatory responses, and regulating immune responses. In addition, we also highlight innovative delivery methods, including intrapericardial administration for immunomodulation, ischemic myocardium-targeting peptides, and functional hydrogel encapsulation that significantly improve exosome retention and bioavailability. The fusion of biological mechanisms and engineering solutions makes MSC-Exo a multifunctional platform for cardiovascular regenerative medicine, with emerging clinical translation potential through optimized delivery systems and precise targeting strategies, in order to provide new ideas for the treatment of cardiovascular diseases with MSC-Exo.
Keywords: MSC-Exo, Myocardial Infarction, Myocardial ischemia-reperfusion injury, Atherosclerosis, Heart Failure
Received: 21 Oct 2025; Accepted: 24 Nov 2025.
Copyright: © 2025 Jin and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zongjun Liu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.